Lyell Immunopharma (LYEL) Common Equity (2019 - 2026)

Lyell Immunopharma's Common Equity history runs 8 years deep, the most recent figure standing at $273.7 million for Q1 2026.

• In Q1 2026, Common Equity fell 18.68% year-over-year to $273.7 million; the TTM figure through Mar 2026 stood at $273.7 million (down 18.68% YoY), while the FY2025 annual figure was $248.2 million, down 35.17% from the prior year.
• Common Equity came in at $273.7 million for Q1 2026 at Lyell Immunopharma, up from $248.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $881.2 million in Q1 2022 to a low of $248.2 million in Q4 2025.
• A 5-year average of $579.1 million and a median of $603.2 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 363.81% in 2022 and sank 47.23% in 2025, its largest moves.
• Lyell Immunopharma's Common Equity stood at $833.3 million in 2022, then fell by 21.4% to $655.0 million in 2023, then sank by 41.55% to $382.8 million in 2024, then plunged by 35.17% to $248.2 million in 2025, then rose by 10.26% to $273.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $273.7 million, $248.2 million, and $329.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison